Executives On The Move: Science Appointments Made At Amneal Pharma And Hemostemix, And Board Changes At Silence Therapeutics
Specialty and generics drug company Amneal Pharmaceuticals hires a CSO and stem cell firm Hemostemix adds a president and CMO. Also, RNAi therapeutics business Silence Therapeutics names a new chairman.
You may also be interested in...
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Executives On The Move: Exits From Takeda Vaccines And Novartis Institutes To CMO Positions And Board Changes At Merck & Co.
Takeda Vaccines VP switches to cancer immunotherapy and vaccine company Bavarian Nordic and Novartis Institutes exec moves to molecular medicines firm Boston Pharmaceuticals, each in the CMO position. Meanwhile, Merck & Co will add a scientific and a strategic expert to its board.